AB0926 Effectiveness of certolizumab pegol in psoriatic arthritis. relationship with smoking status and bmi

• Published in: Annals of the rheumatic diseases Vol. 77; no. Suppl 2; p. 1588
• Main Authors: Campos Esteban, J., Conesa Mateos, A., Fernandez-Prada, M., Expósito-Molinero, R., Rubio Muñoz, P., Lamua-Riazuelo, J.R., Navarro-Alonso, P., Ahijado Guzmán, P., Garcia-Portales, R., Urruticoechea-Arana, A., Gonzalez Fernandez, C.M.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2018
• Subjects: Arthritis; Body mass index; Clinical medicine; Immunotherapy; Monoclonal antibodies; Psoriatic arthritis; Smoking; Statistical analysis; Survival; TNF inhibitors; Tobacco; Tumor necrosis factor-α
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2018-eular.5983

BackgroundPrevious literature have investigated that tobacco and weight in patients with psoriatic arthritis (PsA) is associated with a poorer response to antiTNF.ObjectivesTo investigate the response and survival of Certolizumab pegol (CZP) in PsA patient in daily clinical practice according to their baseline smoking status and Body Mass Index (BMI).MethodsMulticentric cohort of PsA patients treated with CZP according to routine clinical practice. This study was approved by local Ethics Committee. Maximum observation time was 12 months. Effectiveness variables: DAS28 (CRP). Survival rate: Kapplan-Meier.Results262 patients with PsA were included: 43.5% male, mean (SD) age 49.9 (11.9) years, mean (Q1-Q3) disease duration 6.9 (1.9–9.3) years, and 14.9% of patients were HLAB27 positive. Among these, 229 (87.4%) had known smoking status (29.7% smokers and 70.3% never smokers) and 85 (32%) had known BMI (median 26.9 kg/m2, SD 4.7). Statistically significant differences in DAS28 were observed at last visit comparing to baseline in both groups according to BMI and smoking status (table 1).CZP retention rate was 78.5% in non-smokers and 76.7% in smokers. In patients with BMI <25 kg/m2 CZP retention rate was 78.6% compared to 78.9%in patients with BMI ≥25 kg/m2 (figure 1). No statistical differences were observed in both sub-groups.Abstract AB0926 – Table 1DAS28 BaselineBMI<25 kg/m24.6 (0.9)BMI≥25 kg/m24.5 (0.8)Never smokers4.6 (0.9)Smokers4.6 (0.9)Last visitBMI<25 kg/m23.6 (1.1)*BMI≥25 kg/m23.9 (1.0)*Never smokers3.9 (1.0)#Smokers3.3 (0.8)#*p<0,05, Wilcoxon test; #p<0.001 T-Student’s test (last visit vs basal).Abstract AB0926 – Figure 1CZP Retention Rate according to BMI and smoking status in PsA patients.ConclusionsIn this daily clinical practice study of patientes with PsA treated with certolizumab pegol there was a significant decrease in DAS28-CRP independent of smoking status and BMI. No differences were found in the retention rate of certolizumab pegol based on these two variables.Disclosure of InterestJ. Campos Esteban: None declared, A. Conesa Mateos: None declared, M. Fernandez-Prada: None declared, R. Expósito-Molinero: None declared, P. Rubio Muñoz: None declared, J. R. Lamua-Riazuelo: None declared, P. Navarro-Alonso: None declared, P. Ahijado Guzmán: None declared, R. Garcia-Portales Consultant for: Celgene, Speakers bureau: UCB, Pfizer, Roche, A. Urruticoechea-Arana: None declared, C. Gonzalez Fernandez Consultant for: Celgene, MSD, Novartis, Janssen, Speakers bureau: UCB, Abbvie, Pfizer, BMS, Roche, Celgene, Janssen